30 Oct 2020 16:33
Result of Annual General Meeting
Oxford, U.K. 30 October 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, announces that at its virtual Annual General Meeting ('AGM') held today at 2pm GMT, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM is contained in the notice of AGM published on 06 October 2020 which is available on Sensyne's website.
Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:
"Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term, we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.
Most importantly we embody a better way to build technology companies - a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."
For information, full details of the votes received were as follows and all information will shortly be posted on the Company's website (www.sensynehealth.com):
Res No. | Votes For | % | Votes Against | % | Votes Total | % I.S.C. | Votes Withheld |
01 | 76,467,429 | 100.00% | 0 | 0.00% | 76,467,429 | 59.47 | 0 |
02 | 74,777,158 | 97.79% | 1,690,271 | 2.21% | 76,467,429 | 59.47 | 0 |
03 | 75,488,059 | 98.72% | 976,870 | 1.28% | 76,464,929 | 59.47 | 2,500 |
04 | 76,434,779 | 99.96% | 32,650 | 0.04% | 76,467,429 | 59.47 | 0 |
05 | 76,467,429 | 100.00% | 0 | 0.00% | 76,467,429 | 59.47 | 0 |
06 | 74,924,805 | 97.98% | 1,542,624 | 2.02% | 76,467,429 | 59.47 | 0 |
07 | 76,467,429 | 100.00% | 0 | 0.00% | 76,467,429 | 59.47 | 0 |
08 | 76,464,511 | 100.00% | 2,918 | 0.00% | 76,467,429 | 59.47 | 0 |
09 | 76,465,159 | 100.00% | 2,270 | 0.00% | 76,467,429 | 59.47 | 0 |
10 | 76,426,569 | 99.95% | 36,860 | 0.05% | 76,463,429 | 59.47 | 4,000 |
11 | 76,408,258 | 99.96% | 29,171 | 0.04% | 76,437,429 | 59.45 | 30,000 |
12 | 76,408,758 | 99.97% | 26,171 | 0.03% | 76,434,929 | 59.45 | 32,500 |
13 | 75,423,313 | 98.63% | 1,044,116 | 1.37% | 76,467,429 | 59.47 | 0 |
At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:
"During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Michael Norris, Interim Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Oliver Jackson | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 77 0286 8207 |
Mary-Jane Elliott | |
Sukaina Virji | |
Melissa Gardiner | |
CSCSensynehealth@consilium-comms.com |
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com